Recently, Jilin Laiwo Medical Technology Co., Ltd., with its profound accumulation and unremitting innovation in the field of hemodialysis treatment, successfully obtained the Class III medical device registration certificate issued by the National Medical Products Administration for its independently developed new product - hemodialysis concentrate (A liquid B dry powder). This achievement not only marks an important breakthrough for the company in the field of hemodialysis treatment, but also brings good news to the vast number of dialysis patients.

Hemodialysis concentrate
       Laiwo Medical R&D and production is a type of blood dialysis fluid that minimizes the presence of thermal substances in the fluid and is free from microbial contamination.
       Hemodialysis concentrate minimizes the presence of pyrogens in the dialysate to the greatest extent possible, without microbial contamination. It can significantly reduce the occurrence of chronic inflammation and dialysis related amyloidosis, reduce oxidative stress and cardiovascular disease incidence, effectively improve the nutritional status and quality of life of hemodialysis patients, protect residual renal function of hemodialysis patients, significantly improve dialysis quality, and improve long-term survival rate of patients.

Product Features

A concentrated solution is acidic and contains components such as sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, etc

B dry powder is alkaline, mainly composed of sodium bicarbonate

       Ultra pure hemodialysis concentrate minimizes the presence of pyrogens in the dialysate and is free from microbial contamination. It can significantly reduce the occurrence of chronic inflammation and dialysis related amyloidosis, reduce oxidative stress and cardiovascular disease incidence, effectively improve the nutritional status and quality of life of hemodialysis patients, protect residual renal function of hemodialysis patients, significantly improve dialysis quality, and improve long-term survival rate of patients.

Product advantages
1. Ultra pure dialysate is safer and more stable
2. Significantly reduce and improve the patient's micro inflammatory response
3. Increase sensitivity to EPO
4. Reduce β 2-microglobulin levels and dialysis amyloidosis (carpal tunnel syndrome)
5. Improving the nutritional status of dialysis patients
6. Protecting residual renal function

Product scope of application
       This product is suitable for hemodialysis treatment of patients with acute and chronic renal failure.
       In the future, Laiwo Medical will continue to uphold the corporate spirit of "healthy life, Laiwo quality", continuously increase research and development investment and technological innovation, and provide patients with safer, more effective, and convenient medical products. At the same time, we will actively respond to the national policy call for the development of the medical and health industry, and contribute more to promoting the development of China's medical and health industry.